Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 10/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531714 | 0.78 | PRKCQ (0.49) | EGFRSYKFLT1PRKCQPRKCD | |
| SCHEMBL5520629 | 0.77 | PRKCQ (0.53) | PRKCQPRKCD | |
| SCHEMBL5524656 | 0.76 | PRKCQ (0.72) | ABL1EGFRSYKMAP3K11FLT1 | |
| SCHEMBL5526507 | 0.76 | PRKCQ (0.49) | EGFRFLT1PRKCQPRKCD | |
| SCHEMBL5513949 | 0.75 | PRKCQ (0.53) | ABL1BCRPRKCQPRKCD | |
| SCHEMBL5520823 | 0.75 | PRKCQ (0.75) | PRKCQPRKCD | |
| SCHEMBL5662149 | 0.75 | SYK (0.45) | EGFRSYK | |
| SCHEMBL5515583 | 0.75 | PRKCQ (0.54) | PRKCQPRKCD | |
| SCHEMBL5532194 | 0.74 | PRKCQ (0.73) | ABL1EGFRSYKMAP3K11FLT1 | |
| SCHEMBL6625762 | 0.74 | EGFR (0.53) | EGFRSYKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | ABL1 62/4885BCR 1413/4885EGFR 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.